Fundraising FoxMethuselah Funds — Full Portfolio
8 tracked investments · listed companies and verified rows first
Leucadia Therapeutics is developing Arethusta, a first-in-class outpatient treatment for Alzheimer's disease, initially aiming to reverse mild cognitive impairment associated with the condition before targeting prevention and cure.
BiotechHealthtechLongevity
Oisín Biotechnologies develops non-viral genetic therapies built on its Fusogenix Proteo-Lipid Vehicle (PLV) delivery platform, which delivers DNA and RNA payloads to tissues throughout the body and allows repeat dosing.
BiotechHealthtechLongevitySeattle, US
Matthew Scholz(Executive Officer, Director)inEric Garcia(Executive Officer)inStephen Hilbert(Executive Officer)John Lewis(Executive Officer)inGary Hudson(Executive Officer, Director)in
BoardDavid Gobel(Director)
Co-investorsIKJ CapitalHealthspan Capital
OncoSenX is a late-stage pre-clinical cancer therapeutics company developing treatments that target solid tumors based on transcriptional activity.
BiotechDeep TechHealthtechSeattle, US
Matt Scholz(Executive Officer, Director)John Lewis(Executive Officer, Director)inGary Hudson(Director)in
Co-investorsHelios CapitalMethuselah FoundationChainFund CapitalInvesco
Viscient Biosciences develops drugs by studying human 3D tissue models combined with multi-omics analysis to understand disease mechanisms.
BiotechDeep TechDigital HealthSan Diego, US
Keith Murphy(Executive Officer, Director)in
Co-investorsHarmonix FundMethuselah FoundationThynk Capital
Volumetric Biotechnologies, acquired by 3D Systems in 2021, develops bioprinting materials and vascularized human tissue constructs.
BiotechDeep TechHealthtechMedical DevicesHouston, US
Jordan Miller(President)inBagrat Grigoryan(COO)in
Co-investorsGaingelsGoAhead VenturesHarmonix FundHelios CapitalJoyance PartnersJude Gomila+21 more
__Twitter.png)
Winsantor is a clinical-stage biotechnology company developing treatments for peripheral neuropathies, including diabetic peripheral neuropathy and chemotherapy-induced peripheral neuropathy.
BiotechHealthtechMedical DevicesSan Diego, US
Stan Kim(Executive Officer, Director)inNigel Calcutt(Director)
Co-investorsThynk Capital
X-Therma develops a proprietary peptoid-based technology that inhibits ice crystal formation to enable long-term sub-zero preservation and transport of cells, tissues, organs, and other biologics.
BiotechDeep TechMedical DevicesNew MaterialsRichmond, US
Xiaoxi Wei(Founder & CEO)inMark Kline(Executive Officer, Director)inJohannes Weggemann(Director)
Co-investorsAurum Venture PartnersDellin InvestmentsLIFTTMethuselah FoundationPortfoliaVU Venture Partners+1 more
Other
Tracked investments with no reachable website or further public details — typically companies that wound down, renamed, or were absorbed.
Turn
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.